666P Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patientsSarah P. Blagden, David J. Harrison, S.N. Symeonides et al.|Annals of Oncology|2024Cited by 3
Abstract C032: NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide:701 studySarah P. Blagden, Elizabeth Ruth Plummer, Aglaia Skolariki et al.|Molecular Cancer Therapeutics|2023Cited by 1
566TiP A first-in-human study of NUC-7738, a ProTide transformation of 3’-deoxyadenosine, in patients with advanced solid tumours (NuTide:701)Sarah P. Blagden, Ruth Plummer, Francesca Aroldi et al.|Annals of Oncology|2021Cited by 0